title: Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo.
abstract: Therapeutic effects of hybrid liposomes (L-α-dimyristoylphosphatidylcholine (DMPC)/docosahexaenoic acid (DHA)) composed of 50 mol% DMPC and 50 mol% DHA on the metastasis of human colon carcinoma (HCT116) cells were examined in vivo. DMPC/DHA having a hydrodynamic diameter less than 100 nm were preserved for one month. Remarkably high therapeutic effects were obtained in the hepatic metastasis mouse models of HCT116 cells after the intravenous injection of DMPC/DHA. The histological analysis indicated the induction of apoptosis was observed in the liver section of the hepatic metastasis mouse models treated with DMPC/DHA in vivo. Furthermore, prolonged survival was obtained in the hepatic metastasis mouse models after the treatment with DMPC/DHA. Therapeutic effects of DMPC/DHA without any drugs on the hepatic metastasis were revealed on the basis of histological and biochemical analyses for the first time in vivo.
authors.affiliation: Division of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ichihara
authors.forename: Keiko
authors.initials: K
authors.lastname: Zako
authors.forename: Yuji
authors.initials: Y
authors.lastname: Komizu
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Ueoka
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D004355:Drug Stability; D005260:Female; D045325:HCT116 Cells; D006801:Humans; D007275:Injections, Intravenous; D008081:Liposomes; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D051379:Mice; D016513:Mice, SCID; D010316:Particle Size; D014677:Pharmaceutical Vehicles / Q000737:chemistry; D011897:Random Allocation; D016019:Survival Analysis; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D014677:Pharmaceutical Vehicles; D004281:Docosahexaenoic Acids; D004134:Dimyristoylphosphatidylcholine